Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis
Obesity · 2026-09 · 34 (S2) · 132-145
DOI: 10.1002/oby.70231 ↗At a glance
Journal article in Obesity, published online on 2026-06-14. Written by Regina Castaneda and 17 co-authors. Institution: Division of General Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA. Major MEDLINE topics: Tirzepatide, Weight Loss, Obesity, Anti-Obesity Agents. Cited 2 times so far (Crossref); 38 references. The full text is freely available in PubMed Central. Funded by: Mayo Clinic Center for Women's Health Research.
Abstract (original language)
Objective
This study assessed the impact of sex and age on weight loss outcomes in patients receiving tirzepatide in real‐world clinical practice.
Methods
We conducted a retrospective cohort study of adults with overweight or obesity who initiated tirzepatide at Mayo Clinic between June 2022 and May 2024 and completed ≥ 12 months of continuous therapy. Primary outcome was total body weight loss percentage (TBWL%) at 15 months, stratified by sex and age groups (≤ 45, 46–59, ≥ 60 years).
Results
Among 1039 patients (57% women; mean age 56 ± 11 years), women achieved significantly greater TBWL% than men after 15 months of treatment (15.1% vs. 10.7%, p < 0.001). Patients aged ≤ 45 years had greater weight loss than those ≥ 60 years (15.1% vs. 12.3%, p = 0.024). In multivariable analyses, greater weight loss was independently associated with female sex, absence of type 2 diabetes, no prior obesity medication use, no concomitant weight gain‐promoting medications, and higher tirzepatide dosage. Age was not an independent predictor.
Conclusions
Sex, but not age, predicted weight loss with tirzepatide among individuals using the medication continuously for ≥ 12 months. These findings underscore the importance of incorporating sex‐specific considerations into personalized obesity treatment strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of General Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Endocrinology, Mayo Clinic, Jacksonville, Florida, USA.
- Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Internal Medicine, Henry Ford Rochester Hospital, Detroit, Michigan, USA.
- Division of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID profiles: Regina Castaneda, Dima Bechenati, Rene de J Rivera Gutierrez, Maria A Espinosa, Jose Villamarin, Elif Tama, Nancy Safwan, Sima Fansa, Alfredo Verastegui, Allyson W McNally, Kristin C Cole, Stacey J Winham, Tamim I Rajjo, Andres Acosta, Stephanie S Faubion, Chrisandra L Shufelt, Maria D Hurtado Andrade
Funding
- Mayo Clinic Center for Women's Health Research
Cite
APA
Castaneda, R., Bechenati, D., Rivera Gutierrez, R. J., Espinosa, M. A., Villamarin, J., Tama, E., Safwan, N., Fansa, S., Verastegui, A., McNally, A. W., Meek, J. L., Cole, K. C., Winham, S. J., Rajjo, T. I., Acosta, A., Faubion, S. S., Shufelt, C. L., & Hurtado Andrade, M. D. (2026). Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis. Obesity, 34(S2), 132-145. https://doi.org/10.1002/oby.70231
Vancouver
Castaneda R, Bechenati D, Rivera Gutierrez RJ, Espinosa MA, Villamarin J, Tama E, et al. Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis. Obesity. 2026;34(S2):132-145. doi:10.1002/oby.70231
BibTeX
@article{Castaneda2026,
author = {Castaneda, Regina and Bechenati, Dima and Rivera Gutierrez, Rene de J and Espinosa, Maria A and Villamarin, Jose and Tama, Elif and Safwan, Nancy and Fansa, Sima and Verastegui, Alfredo and McNally, Allyson W and Meek, Jesse L and Cole, Kristin C and Winham, Stacey J and Rajjo, Tamim I and Acosta, Andres and Faubion, Stephanie S and Shufelt, Chrisandra L and Hurtado Andrade, Maria D},
title = {Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis},
journal = {Obesity},
year = {2026},
volume = {34},
number = {S2},
pages = {132--145},
doi = {10.1002/oby.70231}
}
EUVIMED